RenovoRx’s TIGeR-PaC pivotal study is currently enrolling newly diagnosed Locally Advanced Pancreatic Cancer patients. This study is a randomized study of Trans-Arterial Micro-PerfusionTM (TAMPTM) versus systemic chemotherapy. 

More information and a list of active clinical sites can be found here.

The RenovoCathTM

Simplicity, Versatility, Targeted Delivery

Innovative Dual Balloon Design = Targeted Delivery

We offer a versatile catheter system for use with both standard and developing therapeutic agents.

RenovoCath in action:  Gonadal vein sclerosis

RenovoCath in Action:

Gonadal vein sclerosis

RenovoCath in Action:

Targeting a pancreatic tumor

RenovoCath in Action:

Targeting a liver tumor

About RenovoRX

RenovoRx is a medical device company headquartered in Silicon Valley, California.

We are developing solutions for targeted delivery of diagnostic, and therapeutic agents including chemotherapeutic drugs to selected sites in the peripheral vascular system.

In the News

view all
  • RenovoRx Announces $10 Million Financing for Innovative Treatment for Advanced Pancreatic Cancer

    Company’s RenovoCath System Has Received Orphan Drug Designation from the FDA for its Innovative Approach. LOS ALTOS, Calif. – May 23, 2018 – RenovoRx, Inc., a medical technology company developing an innovative catheter-based approach to treating pancreatic cancer, today announced … Continue reading

  • Researchers Report Survival Benefits with Use of RenovoCath™ in Patients with Locally Advanced Pancreatic Tumors

    LOS ALTOS, CA – RenovoRx, a Silicon Valley-based medical device company, announced today that two teams of researchers treating patients with advanced non-metastatic pancreatic tumors reported beneficial effects including lengthened survival rates when using the company’s RenovoCath™ with targeted chemotherapy. … Continue reading

  • Presentation of Data on Intra-arterial Targeted Delivery of Gemcitabine in Treatment of Loco-regional Pancreatic Tumors

    Aim: A dose escalation study of Gemcitabine for treatment of unresectable pancreatic cancer, using a targeted intra-arterial delivery catheter (RenovoCath™). Methods: 20 patients at two centers were enrolled with a fourstage dose escalation of gemcitabine up to 1000 mg/m2. Enzyme … Continue reading